Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis

Table 1

Characteristics of the eligible RCTs.

Study (year)	Study type	Histology	Endpoint	Treatment arm	Patient (no.)	Pancreatitis		AMY		Lipase
						(G1–5)	(G3–5)	(1–5)	(3–5)	(1–5)	(3–5)
Ribas et al., 2013 [6]	RCT III	MM	OS	Tremelimumab at 15 mg/kg 90 ds	325	3	3	NA	NA	NA	NA
				Chemotherapy control	319	0	0	NA	NA	NA	NA
Know, 2014	RCT III	prostate Ca	OS	Ipilimumab 10 mg/kg q3w	393	NA	NA	2	2	3	1
				Placebo	396	NA	NA	1	0	3	2
Eggermont et al., 2015 [7]	RCT III	MM	PFS	Ipilimumab 10 mg/kg q3w	471	NA	1	NA	NA	43	1
				Placebo	474	NA	0	NA	NA	30	0
Maio et al., 2017 [8]	RCT IIb	Mesothelioma	OS	Tremelimumab 10 mg/kg q4w	380	2	1	NA	0	18	11
				Placebo	189	0	0	NA	1	4	3
Brahmer et al., 2015 [24]	RCT III	NSCLC	OS	Nivolumab 3 mg/kg q2w	131	NA	NA	NA	NA	1	1
				Chemotherapy control	129	NA	NA	NA	NA	0	0
Robert et al., 2011 [4]	RCT III	MM	OS	Nivolumab 3 mg/kg q2w	206	NA	NA	NA	1	NA	NA
				Chemotherapy control	205	NA	NA	NA	0	NA	NA
Weber et al., 2015 [9]	RCT III	MM	ORR	Nivolumab 3 mg/kg q2w	268	NA	2	NA	NA	NA	3
				Chemotherapy control	102	NA	0	NA	NA	NA	1
Herbst et al., 2016 [10]	RCT III	NSCLC	OS	Pembrolizumab 2 mg/kg q2w	339	3	2	NA	NA	NA	NA
				Pembrolizumab 10 mg/kg q2w	343	0	0	NA	NA	NA	NA
				Chemotherapy control	309	0	0	NA	NA	NA	NA
Reck et al., 2016 [11]	RCTIII	NSCLC	PFS	Pembrolizumab 200 mg q3w	154	NA	1	NA	NA	NA	NA
				Chemotherapy control	150	NA	0	NA	NA	NA	NA
Ribas et al., 2015 [12]	RCT II	MM	ORR	Pembrolizumab 2 mg/kg q2w	178	1	1	NA	NA	NA	NA
				Pembrolizumab 10 mg/kg q2w	179	3	1	NA	NA	NA	NA
				Chemotherapy control	171	1	1	NA	NA	NA	NA
Rittmeyer et al., 2017 [13]	RCT II	NSCLC	OS	Atezolizumab 1200 mg q3w	609	NA	0	NA	NA	NA	NA
				Chemotherapy control	578	NA	1	NA	NA	NA	NA
Hodi et al., 2016 [14]	RCT II	MM	ORR	Ipilimumab 3 mg/kg q3w; +nivolumab 1 mg/kg q3w	94	2	2	11	2	17	2
				Ipilimumab 3 mg/kg q3w	46	0	0	0	0	2	0
Antonia et al., 2016 [22]	RCT II	SCLC	ORR	Ipilimumab 3 mg/kg q3w; +nivolumab 1 mg/kg q3w	61	NA	NA	4	1	7	5
				Ipilimumab 1 mg/kg q3w; +nivolumab 3 mg/kg q3w	54	NA	NA	2	0	0	0
				Nivolumab 3 mg/kg q2w	98	NA	NA	1	1	0	0
Larkin et al., 2015 [15]	RCT III	MM	OS/PFS	Ipilimumab 3 mg/kg q3w; +nivolumab 1 mg/kg q3w	313	NA	2	NA	NA	NA	2
				Nivolumab 3 mg/kg q3w	313	NA	1	NA	NA	NA	0
				Ipilimumab 3 mg/kg q3w	311	NA	1	NA	NA	NA	0
Robert et al., 2015 [16]	RCT III	MM	OS	Pembrolizumab 10 mg/kg q2w	278	NA	0	NA	NA	NA	NA
				Pembrolizumab 10 mg/kg q3w	277	NA	1	NA	NA	NA	NA
				Ipilimumab 3 mg/kg q3w	256	NA	0	NA	NA	NA	NA

MM: melanoma; NSCLC: nonsmall cell lung cancer; DTIC: Dacarbazine; gp100: gp100 vaccine; DOX: docetaxel; OS: overall survival; ORR: objective response rate; NA: not available.